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Abstract
Background: Lymphangioleiomyomatosis (LAM) is a progressive lung disease that impairs health-related quality of
life (HRQL).
Objective: To develop and conduct initial testing of ATAQ-LAM (A Tool to Assess Quality of Life in LAM).
Methods: A pilot version of the questionnaire was administered to respondents with LAM. We used a deletion algorithm
to retain items and then applied multi-trait scaling to place retained items into appropriate domains, thus generating the
ATAQ-LAM. Rasch analysis was used to assess item fit to a unidimensional model of HRQL. We determined internal
consistency (IC) and floor and ceiling effects of ATAQ-LAM scores and conducted analyses aimed at supporting
the validity of ATAQ-LAM.
Results: Sixty-nine LAM patients provided response data. Thirty-two items survived the deletion algorithm. Scaling
suggested ATAQ-LAM should have a four-domain structure (Exertional dyspnea, IC = 0.94; Cough, IC = 0.91; Fatigue,
IC = 0.91; Emotional Well-Being, IC = 0.89). All items fit the Rasch model. Among 17 respondents with spirometry
within three months of questionnaire completion, three of five ATAQ-LAM scores correlated with FEV1% (Exertional
Dyspnea: r = −0.72, p = 0.001; Fatigue: r = −0.62, p = 0.007 and total: r = −0.53, p = 0.02). Compared with those in the
highest tertile of FEV1%, subjects in the lowest tertile had greater ATAQ-LAM total (121.8 ± 14.3 vs. 79.8 ± 13.1, p = 0.04),
Exertional Dyspnea (54.4 ± 6.3 vs. 25.5 ± 5.8, p = 0.005) and Fatigue (2.8 ± 2.4 vs. 14.8 ± 2.3, p = 0.03) scores, indicating
greater impairment in HRQL.
Conclusions: ATAQ-LAM is a disease-specific instrument designed to assess HRQL in LAM patients. Additional studies are
needed to generate data in support of its validity as an instrument capable of assessing HRQL over time in LAM patients.
Introduction
Lymphangioleiomyomatosis (LAM) is an incurable, low-
grade malignancy that occurs either sporadically (S-LAM)
or as a result of tuberous sclerosis complex (TSC-LAM).
LAM affects predominantly women of child-bearing age,
and although its rarity creates challenges in generating
epidemiological estimates, LAM has been reported to
occur in about 5 persons per 100,000 in the U.S [1–3]. In
LAM, viable lung tissue is progressively replaced by thin-
walled cysts, leading to an obstructive ventilatory defect
and increasingly severe dyspnea [4].
Besides dyspnea, other intrusive symptoms include
cough and fatigue. Given the symptoms, need for
supplemental oxygen and the anxiety of living with a po-
tentially life-shortening illness, it stands to reason that
health-related quality of life (HRQL) may be impaired in
patients living with LAM [5]. Recent advances in under-
standing the pathogenesis of LAM, including the identi-
fication of promising therapeutic targets, have paved the
way for testing novel or existing drugs [6]. A trial (called
MILES and designed to assess the efficacy and safety of
rapamycin in LAM) showed that the drug halted LAM
progression (as defined by decline in the one-second
forced expiratory volume [FEV1]) and was associated
with improvements in scores from one generic HRQL
measure (the EuroQOL visual analogue scale for quality
of life) but not other generic (the General Well-Being
Questionnaire or the SF-36) or a chronic obstructive
pulmonary disease specific instrument (the St. George’s
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Respiratory Questionnaire or SGRQ) [6]. Whether a
LAM-specific HRQL questionnaire would have per-
formed similarly (or better) is unknown, because one
was not available for use at the time MILES was con-
ducted; however, it is believed that carefully developed,
patient-tailored, and disease-specific instruments are
likely to be more sensitive to underlying change than
generic instruments [7].
We previously conducted seven focus groups with 37
TSC- or S-LAM patients to better understand how
LAM affects patients’ lives [5] and to gather data that
we used to develop content (domains and items) for a pre-
liminary version of a LAM specific HRQL instrument.
Shortness of breath, fatigue and cough were the symptoms
mentioned in all seven groups, but shortness of breath
was by far the most bothersome. The psychological experi-
ences of living with LAM included frustration with the
physical limitations LAM imposes; worry over living with
an unpredictable, incurable, life-threatening illness; and
myriad issues associated with assuming the “patient role”.
Such issues included a loss of identity, the perception of
being viewed as weak when yielding to physical limita-
tions, embarrassment when using supplemental oxygen,
and the loss of control that came with needing to take
medication to fight the disease.
Here, we describe the development and initial validity
analyses of ATAQ-LAM (A Tool to Assess Quality of
Life in LAM), a LAM-specific, multi-dimensional instru-
ment to assess HRQL.
Methods
Phase I: Item pool development and evaluation
Guided by qualitative content analysis of the transcripts
from the focus groups [5] and clinical experience caring
for LAM patients, we developed a pool of 56 items
comprising a preliminary version of ATAQ-LAM. The
qualitative work revealed themes including physical
manifestations of shortness of breath, fatigue, cough,
chest sensations, difficulty sleeping, and GI issues along
with the psychological manifestations mentioned above.
In developing the items, we elected to focus on the
most “proximal” effects—those that can be most directly
linked back to living with LAM. Thus, the pilot version
of ATAQ-LAM included the generated items grouped
into 10 hypothesized domains: Exertional dyspnea (14
items), Effects of dyspnea (4 items), Chest pain (2 items),
Cough and wheeze (13), Fatigue (7 items), Emotional
well-being (7 items), Relationships (2 items), Sexuality (2
items), Symptom-specific HRQL (4 items), and Global
HRQL (1 item). The recall period was 48 h. Each item
was structured identically: between two contrasting
statements were six numerical response options (1, 2, 3,
4, 5, 6)—a response of “1” indicates the strongest agree-
ment with the statement on the left, and a response of
“6” indicates the strongest agreement with the statement
on the right. Summation scoring was used for the total
and each domain, with higher scores connoting greater
impairment.
Phase II: Item reduction and validation
Subjects and general overview
A convenience sample of subjects was recruited at the
2014 LAMposium in Chicago, Illinois. LAMposium is an
annual, three-day conference that offers patients the op-
portunity to become educated about LAM and to connect
with one another. After providing written, informed con-
sent, each subject completed the pilot version once.
Demographic and clinical data (including most recent per-
cent predicted one-second forced expiratory volume
[FEV1%] results, oxygen- and medication-use) were col-
lected from patient records. After LAMposium, 11 LAM
patients participated in debriefing interviews (Please see
the Supplement for their baseline characteristics). All
themes and items were deemed relevant by interviewees,
and no other new topics or items were suggested, despite
extensive probing.
Ethics, consent and permissions
All participants gave written, informed consent to
participate. The study protocol was approved by the
National Jewish Health Institutional Review Board
(protocol #HS-2774).
Statistical approach
General Summary statistics were generated for baseline
characteristics of the study sample.
Item deletion We began the analysis by passing items
through an item-deletion algorithm. Please see the Supple-
ment for full details. First, items for which fewer than five
response options were used were deleted (N = 3). Next,
items missing responses from greater than 20 % of the
sample were deleted (N = 2). Surviving items with greater
than 49 % of respondents scoring at the floor (N = 13) or
ceiling (N = 0) were considered for deletion, one of which
was retained. Other items (N = 7) were deleted for item-
item correlations > 0.7. Lastly, after thoughtful consider-
ation, two “relationship” items were deleted because of
concerns over lack of specificity to the experience of living
with LAM. Ultimately, 32 items in 8 domains were
retained: Exertional dyspnea (8 items), Effects of dyspnea
(4 items), Chest pain (1 item), Cough (5 items), Fatigue (4
items), Emotional well-being (5 items), Symptom-specific
HRQL (4 items) and global HRQL (1 item). The lone
Chest pain item was moved to the Symptom-specific
HRQL domain (thus yielding 7 domains).
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Item scaling We began the examination of the 32
retained items with a multi-trait scaling analysis, which
is a method to address internal consistency reliability,
item convergence, and item discrimination [8]. This ana-
lysis generates a correlation matrix, with each row repre-
senting an item and each column a hypothesized
domain. This matrix allows for evaluation of the extent
to which an item correlates with its hypothesized do-
main. An item that correlates at a level of 0.3 or greater
with its hypothesized domain possesses convergent val-
idity, and an item whose correlation with its hypothe-
sized domain is significantly greater than its correlation
with any other domain possesses discriminant validity
[8]. Meng and colleagues’ method [9] was used to test
whether the difference between these correlation coeffi-
cients was statistically significant. With results from this
analysis, items can be rescaled (moved from one domain
to another, better-fitting, domain), thus yielding the most
systematically-structured domains. At the end of this ana-
lysis, redistribution yielded four domains (Exertional dys-
pnea, Cough, Fatigue, and Emotional well-being) and
three other items that contribute to a total score but do
not belong to any domain. Please see the Additional file 1
for full details.
Rasch analysis Next, we subjected all items in aggre-
gate to Rasch analysis (Winsteps, Version 3.69.1.14,
www.winsteps.com). The mathematics of the Rasch
model locates items and patients on the same scale
according to—for an item—the level of HRQL impair-
ment it signifies and—for a patient—her level of
HRQL impairment (as determined by her responses
to all items) [10]. Rasch uses the difference between
item and patient location—many terms have been
used, but here we refer to these locations as item dif-
ficulty and patient severity, respectively—to model the
probability of responses to each item. Because Rasch
analysis is based on Guttman scaling, a patient’s en-
dorsement of any item implies her endorsement of
less difficult items (i.e., items of lesser difficulty or
lower on the domain). Rasch analysis allows deter-
mination of whether a dataset adheres to fundamental
measurement properties, an important one being uni-
dimensionality—items function together to assess a
singular construct (in the case of ATAQ-LAM, it
would be LAM-specific HRQL). We assessed item fit
by using the infit mean square statistic; values from
0.5-1.5 are considered useful for measurement, and
values greater than 2.0 degrade measurement [11].
Performance characteristics and validity Summation
scoring was used for each domain and total. For each
domain, we calculated mean scores, internal consistency
reliability using Cronbach’s coefficient alpha, [12] and
the percentage of respondents at their floor and ceiling
values. In the “validity analyses,” we used the Pearson
product–moment method to examine correlations be-
tween ATAQ-LAM scores and FEV1% (among patients
who performed spirometry within three months of com-
pleting ATAQ-LAM). We hypothesized that scores from
all but the cough domain would be significantly corre-
lated with FEV1%. We also hypothesized that ATAQ-
LAM scores would be greater (connoting more impaired
HRQL) among patients with more severe LAM; we
tested this hypothesis by conducting two analyses: 1) we
used ANOVA to compare ATAQ-LAM scores among
three subgroups defined by tertiles of FEV1%; and 2) we
used t tests to compare ATAQ-LAM scores between
subjects using—versus not using—supplemental oxygen.
Analyses other than Rasch were performed using SAS
Version 9.3 software (SAS, Inc.; Cary, NC). We consid-
ered p < 0.05 to represent statistical significance.
Results
The sample included 69 female subjects with a broad
range of LAM duration (Table 1). Nearly half the sub-
jects were taking rapamycin. Among the 17 subjects
with useable spirometry data, mean FEV1% suggested
moderate obstruction.
Figure 1 shows the multi-trait correlation matrix and
heat map for the 29 items within the four domains.
Eighty one (of 96) comparisons (shown in green) in the
matrix were scaling successes (correlation between an
item and its hypothesized domain was significantly
stronger than the correlation between the item and any
of its three non-hypothesized domains). For the
remaining 15 comparisons, including the 2 where the
correlation coefficient was greater in a non-hypothesized
domain than the hypothesized domain (shown in or-
ange), there was no statistical difference.
All items fit the Rasch model. Figure 2 shows the posi-
tions of the thresholds between response options for
each item along with other items in its domain. Table 2
shows some of the performance characteristics of the
ATAQ-LAM domains and total. Please see the Supplement
for a copy of ATAQ-LAM.
Three of five ATAQ-LAM scores correlated with
FEV1% (Exertional Dyspnea: r = −0.72, p = 0.001; Cough:
r = 0.05, p = 0.84; Fatigue: r = −0.62, p = 0.007; Emotional
Well-being: r = −0.24, p = 0.34; total r = −0.53, p = 0.02).
Compared to subjects within the highest tertile of FEV1%
(values >79), those in the lowest tertile (values <50 %) had
significantly greater scores for three domains: 1) ATAQ-
LAM total (Fig. 3, 121.8 ± 14.3 vs. 79.8 ± 13.1, p = 0.04); 2)
Exertional Dyspnea (54.4 ± 6.3 vs. 25.5 ± 5.8, p = 0.005)
and 3) Fatigue (22.8 ± 2.4 vs. 14.8 ± 2.3, p = 0.03). But as
hypothesized, there was no difference for Cough (16.2 ±
10.0 vs. 16.0 ± 6.1, p = 0.97). Subjects using supplemental
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oxygen had significantly higher mean ATAQ-LAM scores
(all except for the Cough domain) than subjects who did
not use supplemental oxygen (Table 3).
Discussion
We developed ATAQ-LAM (“A Tool to Assess Quality of
Life in LAM”), a 32-item questionnaire to assess HRQL in
patients with LAM—a cystic lung disease with intrusive
symptoms that affect how patients feel and function. Im-
portantly, and in accordance with the movement to more-
meaningfully include patients in the research enterprise,
ATAQ-LAM was built by incorporating LAM patients’
perspectives at the ground level (in item generation).
Through item deletion, we were left with items that cover
the most prominent, important and proximal effects of
LAM-related HRQL.
In 2002, the Scientific Advisory Committee (SAC) of the
Medical Outcomes Trust [13] described standards for
eight attributes that HRQL instruments should possess,
including: 1) conceptual and measurement model; 2) reli-
ability; 3) validity; 4) responsiveness; 5) interpretability; 6)
respondent and administrative burden; 7) alternative
forms; and 8) cultural and language adaptations. Although
there is much more work to be done, the development
strategy and analyses performed here confirm that certain
psychometric properties—and by extension, certain SAC
standards—of ATAQ-LAM are acceptable. The multi-trait
analysis indicated that the final scaling should yield do-
mains responsive to change over time and with the ability
to discriminate between LAM patients with different de-
grees of HRQL impairment. Rasch analysis confirmed that
overall, the items targeted the study sample well: there
was good matching of items to the severity of HRQL im-
pairment. Internal consistency reliability was excellent; the
percent of subjects scoring at the minimum or maximum
for any score suggests a very low possibility for significant
floor or ceiling effects. Missingness was minimal. To
calculate domain scores when responses are missing,
we would suggest imputing responses for missing items
using the mean from the non-missing items in a do-
main (assuming at least half the items in that domain
have responses).
Although “validation” is never truly finished—rather, it
is an ongoing process of testing hypotheses and gather-
ing data—validity of ATAQ-LAM was supported by
three findings: 1) significant correlation, in the expected
direction, between ATAQ-LAM scores and FEV1%; 2)
subjects requiring supplemental oxygen had higher
ATAQ-LAM scores than subjects not requiring supple-
mental oxygen; and 3) ATAQ-LAM scores (total, Exer-
tional Dyspnea and Fatigue) were significantly higher
(more impaired HRQL) for subjects with the lowest FEV1%
compared with subjects with the highest FEV1% values.
The latter reveal that ATAQ-LAM can discriminate
Table 1 Baseline characteristics of study participants
Variable N Results
Female 69























LAM duration, years 69 8.2 ± 7.9 (range 0.03 – 40)
FEV1, L 17 1.70 ± 0.6 (range 0.79 – 2.87)






Sleep + exertion, not at rest 12







LAM lymphangioleiomyomatosis, FEV1% percent predicted one-second forced
expiratory volume, CS/LABA combination inhaled corticosteroid and
long-acting beta-agonist
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between patients with differing levels of LAM severity—and
by extension, differing levels of HRQL impairment.
In a prior study, the SGRQ was observed to possess
validity in LAM [14]. One can presume that by including
items most relevant to patients with LAM (and
excluding those that are not, including several items on
the SGRQ), ATAQ-LAM would be more sensitive to
change than SGRQ; whether this is true remains a ques-
tion that requires further study. In the MILES Trial,
rapamycin halted physiological decline in patients with
Fig. 1 Multi-trait correlation matrix for 29 ATAQ-LAM items that form the Exertional Dyspnea, Cough, Fatigue and Emotional Well-Being subscales.
Footnote: ExD=exertional dyspnea domain; each row is an item, and each column is a domain; values are correlations between an item and each
of the four domains; white=items hypothesized to belong to the domain indicated by its column header; perfect scaling for an item would be
indicated by a row with three green rectangles and one white rectangle that contains an asterisked value; *=correlation in white is significantly
stronger than correlations in same row marked green (scaling success); yellow=probable scaling success—correlation coefficient in white is
greater than correlation coefficient in yellow, but the difference did not reach statistical significance; orange=possible scaling success—correlation
coefficient in white is lesser than correlation coefficient in orange, but the difference did not reach statistical significance
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LAM, but did not lead to significant improvements in
EuroQOL dyspnea or fatigue scores. Although ATAQ-
LAM covers dyspnea and fatigue, the items are distinct
from the EuroQOL, and there is no way to know
whether, if they indeed existed in MILES, true differ-
ences between treatment and placebo arms in these two
domains would have been detected by ATAQ-LAM.
The fact that the Cough domain and Emotional Well-
being scores did not differ between subjects with the
lowest—versus highest—FEV1% values is not terribly
surprising: with only 17 subjects with useable FEV1 data
(spirometry performed within three months of complet-
ing the questionnaire), we may simply have lacked power
to detect such a relationship between cough and FEV1
Fig. 2 Item thresholds derived from Rasch analysis. Footnote: Items are situated on the vertical access and grouped into their respective domains.
Note there are three items (30, 31, and 32) that are included in the ATAQ-LAM total score but do not contribute to any of the four domain scores.
The small figures (circle, square, etc.) on the horizontal line extending from an item label represent threshold positions between response options
for that item. Thresholds represent the logit position where a patient is equally likely to respond to either of two adjacent response options (1 or
2, 2 or 3, 3 or 4, 4 or 5, 5 or 6). For items with four thresholds, only five response options were used by the sample. The solid vertical line at “0”
logits is the mean item difficulty. The dashed vertical line at −0.75 logits represents the mean patient severity. Each “X” along the top of the figure
represents one respondent (LAM patient) and her HRQL severity location (in logits). HRQL impairment ranges from mild (left) to severe (right).
Likewise, item difficulty ranges from easy (likely to be endorsed by someone with even mild HRQL impairment) on the left to difficult (likely to be
endorsed only by someone with the greatest HRQL impairment) on the right
Table 2 Properties of four scales of ATAQ-LAM
Domain alpha Items Mean correlation among
items within the domain
Range possible Range used Mean ± SDa % at floor % at ceiling
Exertional dyspnea 0.94 13 0.75 13-78 13-73 33.9 ± 15.1 4.7 0.0
Cough 0.91 6 0.77 6-36 6-29 13.8 ± 7.1 15.6 0.0
Fatigue 0.91 5 0.81 5-30 5-29 15.4 ± 7.1 6.3 0.0
Emotional 0.89 5 0.77 5-30 5-30 14.3 ± 7.2 10.9 4.7
Total 0.96 32 32-192 35-151 84.6 ± 34.1 0.0 0.0
ATAQ-LAM A Tool to Assess Quality of life in Lymphangioleiomyomatosis, Emotional Emotional Well-Being domain, alpha Cronbach’s coefficient alpha
ahigher scores indicate greater impairment
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if, indeed, one truly exists. More likely is that cough is
independent of FEV1% in LAM. The same may be true
for emotional well-being—there are a number of factors
besides FEV1 that could contribute to a person’s sense
of well-being.
There are limitations to this work that is but the first
of many more needed to build confidence in ATAQ-
LAM. The number of respondents was low; however, for
a rare disease (LAM affects maybe 5000-10,000 people
in the U.S.), 69 respondents is a relatively large propor-
tion of patients. Even so, there were not enough subjects
to allow us to perform a reliable factor analysis. Respon-
dents completed the questionnaire at LAMposium
which may have affected responses—traveling to Chi-
cago for the meeting could have been tiring and/or
stressful; seeing friends (other patients) for the first time
in a long time could have “artificially” increased patients’
moods (and thus HRQL). For the FEV1% analyses, only
17 subjects had spirometry within three months of com-
pleting the questionnaire. In future studies, it will be
helpful to have subjects complete the questionnaire prior
to completing spirometry on the same day—or at least
within the same week. Moving forward, it will also be inter-
esting and informative to administer ATAQ-LAM along-
side other patient-reported outcome measures (e.g., SF-36)
to compare and contrast scores and their implications.
Despite these limitations, we have generated a multi-
dimensional instrument whose items have convergent
and discriminant validity. The instrument possesses ex-
cellent face validity, appears to have acceptable content
validity, and is able to differentiate patients hypothesized
to have differing degrees of HRQL impairment. Through
future work, the validation process will continue (e.g., by
determining the ability of ATAQ-LAM scores to capture
change in HRQL over time) and estimates of the minimal
important difference for its scores can be triangulated.
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Table 3 Comparison of ATAQ-LAM scores between subjects
using any—versus no—supplemental oxygen
Domain Any O2 No O2 Difference, SDU p
N = 29 N = 35
Exertional dyspnea 43.1 ± 14.0 27.7 ± 12.5 15.4 ± 13.1, 1.01 <0.0001
Cough 15.6 ± 6.7 12.5 ± 7.1 3.1 ± 6.9, 0.44 0.08
Fatigue 19.2 ± 7.2 12.7 ± 5.6 6.5 ± 6.3, 0.92 0.0001
Emotional 17.1 ± 8.5 12.3 ± 5.6 4.8 ± 6.9, 0.67 0.01
Total 104.1 ± 34.1 71.3 ± 27.3 32.7 ± 30.2, 0.96 <0.0001
Emotional Emotional Well-Being domain, O2 supplemental oxygen, SDU stand-
ard deviation units for differences
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